[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Capitol Health Call
August 11, 2010

Grassley Boos Ghostwriting

JAMA. 2010;304(6):628. doi:10.1001/jama.2010.1077

Sen Chuck Grassley (R, Iowa), the ranking member of the Senate Finance Committee, is urging the National Institutes of Health (NIH) to incorporate stringent rules against ghostwriting in medical literature into its forthcoming updated disclosure guidelines.

Grassley's recommendation came with the June 24 release of a committee minority staff report that found that the role of pharmaceutical companies in medical publications remains veiled or undisclosed (http://grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf). The report also said the strengthening of journal authorship policies appears to have had only a small effect on ghostwriting and disclosure of industry financing of medical articles (such as hiring a third party to develop articles that cast a company's products in a positive light).

First Page Preview View Large
First page PDF preview
First page PDF preview
×